Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00867698 · ClinicalTrials.gov registry record · Phase 2
AST-120 Used to Treat Mild Hepatic Encephalopathy
A Phase 2 study of Mild Hepatic Encephalopathy, sponsored by Ocera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT00867698: Completed Phase 2 study of Mild Hepatic Encephalopathy, sponsored by Ocera Therapeutics.
NCT00867698 is a Phase 2 study of Mild Hepatic Encephalopathy that has completed, run by Ocera Therapeutics. The registered enrollment target is 148 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00867698, a Phase 2 study of Mild Hepatic Encephalopathy, has completed, sponsored by Ocera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
Conditions Studied
Interventions
- DRUG AST-120
Study Locations (20)
California
- UCSF - Fresno Community Regional Medical Center - Fresno
- UCSD Medical Center - La Jolla
- Scripps Clinic - San Diego
- UCSD Medical Center - San Diego
- California Pacific Medical Center - San Francisco
Florida
- University of Florida College of Medicine - Gainesville
- Mayo Clinic Jacksonville - Jacksonville
- University of Miami, Division of Hepatology / Center for Liver Disease - Miami
Illinois
- Northwestern University, Feinberg School of Medicine - Chicago
- Rush University Medical Center - Chicago
Louisiana
- Delta Research Partners, LLC - Monroe
- Tulane University Health Sciences Center - New Orleans
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconnes Medical Center, Harvard Medical School - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00867698 record still lists
NCT00867698 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Mild Hepatic Encephalopathy appearing as the primary indexed condition, and to 1 intervention - of which AST-120 is the first listed.
NCT00867698 names 20 study sites across 11 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00867698 about?
NCT00867698 is a clinical study titled "AST-120 Used to Treat Mild Hepatic Encephalopathy". The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.
What is the current status of trial NCT00867698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2009-03. Estimated completion is 2010-06.
What conditions does trial NCT00867698 study?
This clinical trial studies the following conditions: Mild Hepatic Encephalopathy.
What interventions are being tested in trial NCT00867698?
The interventions under investigation include: AST-120 (DRUG).
Who is sponsoring clinical trial NCT00867698?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00867698 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00867698's enrollment target sits among peer trials
148 491st of 2000 higher than 1,506 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia